Why the study?
Stereotactic arrhythmia radioablation has emerged as a noninvasive salvage therapy for refractory VT, but a comprehensive evaluation of its efficacy, safety, and technical characteristics across available evidence was needed.
Does stereotactic arrhythmia radioablation (STAR) reduce VT burden and mortality in patients with refractory ventricular tachycardia?
Does stereotactic arrhythmia radioablation (STAR) reduce VT burden and mortality in patients with refractory ventricular tachycardia?
Stereotactic arrhythmia radioablation (STAR) provides meaningful VT suppression with a 7% rate of Grade 3+ acute toxicity in patients with refractory ventricular tachycardia, though evidence is limited by wide inter-study heterogeneity.
Answers are grounded in this paper and cite their sources.
STAR shows promise as salvage therapy for refractory VT with 75% VT reduction and 7% severe toxicity; leaves open optimal patient selection and long-term outcomes.
PURPOSE: Stereotactic arrhythmia radioablation (STAR) has emerged as a noninvasive salvage therapy for refractory ventricular tachycardia (VT), particularly in patients ineligible for catheter ablation (CA). This narrative review and pooled analysis evaluates STAR's efficacy, safety, and technical characteristics, integrating evidence from preclinical studies, case reports, case series, and clinical trials. METHODS: A comprehensive literature search identified 88 studies published between 2015 and 2025, comprising 13 preclinical investigations, 50 case reports, 18 case series, and 7 clinical trials. Study-level data were extracted for pooled analyses of 6- and 12-month mortality, VT burden reduction, and Grade 3+ acute toxicity. Subgroup analyses were performed by delivery modality, age, left ventricular ejection fraction (LVEF), and cardiomyopathy type. Grade 3+ acute toxicity occurred in 7% (95% CI: 4%-10%), most commonly heart-failure decompensation or pneumonitis. Subgroup analyses indicated more favorable outcomes in younger patients, non-ischemic cardiomyopathy (NICM), and those with higher baseline LVEF. CONCLUSIONS: STAR achieves meaningful VT suppression with acceptable acute toxicity across multiple delivery modalities. However, wide inter-study heterogeneity underscores the need for standardized endpoint definitions, dosimetric and motion-management protocols, and prospective follow-up registries. Translational preclinical data and emerging clinical evidence collectively support STAR's continued development as a biologically informed cardiac radiotherapy paradigm.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: